Form 4: Biohaven CFO Matthew Buten Reports Stock Transactions and Option Grants

Biohaven's Chief Financial Officer, Matthew Buten, reported the acquisition of shares and stock options, as well as the withholding of shares for tax purposes, on January 5, 2025.

Summary

• Matthew Buten, the Chief Financial Officer of Biohaven Ltd., reported several transactions involving the company's stock on January 5, 2025.
• He acquired 4,250 common shares through the vesting of restricted share units.
• Additionally, 2,561 common shares were withheld by Biohaven to cover tax obligations related to the vesting of restricted share units at a price of $38.64 per share.
• Buten was also granted 104,000 stock options with an exercise price of $38.64, vesting in four equal installments starting January 5, 2025.
• He also received 17,000 restricted share units, vesting in four equal installments starting January 5, 2025.
• After these transactions, Buten directly owns 193,452 common shares and 104,000 stock options, as well as 12,750 restricted share units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative news. The sentiment is neutral to slightly positive due to the alignment of management interests.

Positives

• The vesting of restricted share units and the granting of stock options to the CFO indicate a continued alignment of interests between management and shareholders.
• The vesting schedule of the options and restricted share units encourages long-term commitment from the CFO.

Negatives

• The withholding of 2,561 shares for tax purposes reduces the net increase in Buten's share ownership.

Risks

• The value of the stock options is dependent on the future performance of Biohaven's stock price.
• The vesting of the options and restricted share units is contingent on Buten's continued employment with the company.

Future Outlook

The stock options and restricted share units vest over the next three years, subject to the CFO's continued employment.

Industry Context

This type of filing is standard for publicly traded companies and reflects the compensation practices for executives.

Comparison to Industry Standards

• Stock option and restricted share unit grants are a common form of executive compensation in the biotechnology industry, similar to companies like Amgen, Biogen, and Regeneron.
• The vesting schedules are typical for these types of grants, designed to incentivize long-term performance and retention.
• The tax withholding of shares is a standard practice to cover the tax liabilities associated with the vesting of equity awards.

Stakeholder Impact

• The transactions reported in the Form 4 are likely to be of interest to shareholders as they provide insight into executive compensation and ownership.

Key Dates

Keywords

Biohaven, Matthew Buten, stock options, restricted share units, insider trading, share ownership, executive compensation, Form 4